BioCentury
ARTICLE | Clinical News

Bioniz reports Phase Ib data for T cell malignancies candidate

May 11, 2018 6:30 PM UTC

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a single-blind, placebo-controlled, U.S. Phase Ib trial in 25 healthy volunteers showing that multiple ascending doses of T cell malignancies candidate BNZ-1 led to no serious adverse events or dose-limiting toxicities (DLTs). The company said BNZ-1 also led to an "exposure-related" reduction from baseline in Treg cells, NK cells and CD8+ T cells...